Insmed plans to conduct $80 million public offering of common stock

Bookrunner Leerink Partners, lead managers Piper Jaffray, JMP assist

By Devika Patel

Knoxville, Tenn., Aug. 11 – Insmed Inc. plans to price an $80 million public sale of common stock with a 30-day $12 million greenshoe option, according to a preliminary prospectus supplement filed Monday with the Securities and Exchange Commission.

Leerink Partners is the sole bookrunner, Piper Jaffray and JMP Securities are the lead managers, and H.C. Wainwright & Co., LLC is the co-manager.

Proceeds will be used to obtain regulatory approvals, commercialize Arikayce and increase manufacturing capacity for the commercial launch of Arikayce as well as for clinical development, working capital, debt repayment, capital expenditures, general research and development and other general corporate purposes.

Insmed, based in Richmond, Va., develops treatments for metabolic diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.